X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Kartos is collaborating with Tempus to use the xT assay, a 648-gene panel, to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may benefit from treatment with KRT-232 (navtemadlin, a small molecule MDM2 inhibitor).
Lead Product(s): Navtemadlin
Therapeutic Area: Oncology Product Name: KRT-232
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Tempus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 06, 2022
Details:
The initial focus of the collaboration will be the co-development of multiple CDx claims in blood cancers for Kartos’ KRT-232, a potent and selective oral MDM2 inhibitor that activates p53 to drive tumor cell death in TP53 wild-type cancers.
Lead Product(s): Navtemadlin
Therapeutic Area: Oncology Product Name: KRT-232
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Illumina
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
